About
THE AURON TEAM
A CULTURE OF INNOVATION
Auron was founded by a world class team of physicians and scientists with proven expertise in bringing effective differentiation therapies to patients. Their initial successes highlighted the untapped potential of this transformative approach. Expanding on this knowledge, Auron has built a multi-omic computational platform that has enabled a unique understanding of the dysregulated differentiation pathways in cancer cells and has identified novel drug targets applicable across multiple tumor indications.
David Millan, PhD
Chief Scientific Officer
“Every day I’m inspired by the energy and motivation of our team as we pioneer a new approach to transformative medicines. Our vision is to change the treatment paradigm for a wide range of cancer types for which there are no effective treatment options, and ultimately transform the lives of patients and their families.”
Meet the team
Leadership
Leadership
Kate Yen, PhD
Founder & CEO
David Millan, PhD
Chief Scientific Officer
Thomas Graeber, PhD
Chief Data Officer
Andrea Armstrong
Chief People Officer
Colleen DeSimone
SVP, Finance
Auron Team
Laura Antipov, PhD
Senior Director, Head of R&D Strategy and Operations
Andrea Armstrong
Chief People Officer
Maulasri Bhatta, PhD
Senior Scientist, I
Tori Brown
Executive Assistant & Operations Manager
Betty Chan, PhD
Director, Biochemistry & Biophysics
Joe DeBartolo, PhD
Director, Computational Biology
Colleen DeSimone
SVP, Finance
Thomas Graeber, PhD
Chief Data Officer
Christina Lee
Scientist
David Millan, PhD
Chief Scientific Officer
James Neef
Director, Medicinal Chemistry
Sambad Sharma, PhD
Senior Scientist, II
Sara Sinicropi-Yao, PhD
Principal Scientist, Translational Biology
Peter Slivka, PhD
Director, Translational Biology
Kimberly Straley
Director, Translational Biology
Henry Wilson, PhD
Principal Scientist, Computational Biology
Kate Yen, PhD
Founder & CEO
Founders
Ross Levine, MD
Memorial Sloan Kettering Cancer Center
Eytan Stein, MD
Memorial Sloan Kettering Cancer Center
Matthew Vander Heiden, MD, PhD
Massachusetts Institute of Technology
Kate Yen, PhD
Founder & CEO
Board of Directors
Alexandra Cantley, PhD
Polaris Partners
Anna French, PhD
Qiming Venture Partners USA
Alon Lazarus, PhD
Arkin Bio Ventures
Briggs Morrison, MD
Independent Chairman of the Board
Eric Shiozaki, PhD
DCVC Bio
Kate Yen, PhD
Founder & CEO
Scientific Advisory Board
Stéphane de Botton, MD, PhD
Gustave Roussy Cancer Center
Richard Chesworth, PhD
Former CSO, Kymera Therapeutics
Thomas Graeber, PhD
University of California, Los Angeles
Ross Levine, MD
Memorial Sloan Kettering Cancer Center
Shin-San Michael Su, PhD
Volastra Therapeutics, Inc.
Mikhail (Misha) Roshal, MD, PhD
Memorial Sloan Kettering Cancer Center
Charles Rudin, MD, PhD
Memorial Sloan Kettering Cancer Center
Kimberly Stegmaier, MD
Harvard Medical School and Dana-Farber Cancer Institute
Eytan Stein, MD
Memorial Sloan Kettering Cancer Center
George Thomas, MD
Oregon Health & Science University
Matthew Vander Heiden, MD, PhD
Massachusetts Institute of Technology
Paresh Vyas, MRCP FRCP FRCPath
Oxford University
Investors
These are some of the companies who support our mission:
